Schrodinger SDGR Drug discovery — Deferred revenue, long-term
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Schrodinger in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Schrodinger's drug discovery — deferred revenue, long-term.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Schrodinger's drug discovery — deferred revenue, long-term?
- Schrodinger (SDGR) reported drug discovery — deferred revenue, long-term of $52.82M in Q1 2026.
- How has Schrodinger's drug discovery — deferred revenue, long-term changed year-over-year?
- Schrodinger's drug discovery — deferred revenue, long-term decreased by 42.5% year-over-year, from $91.79M to $52.82M.
- What does drug discovery — deferred revenue, long-term mean?
- This represents the portion of deferred revenue that is expected to be recognized as income beyond the next twelve months. It indicates the long-term stability and visibility of the company's multi-year research collaborations.